Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 7;21(13):3970-7.
doi: 10.3748/wjg.v21.i13.3970.

Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma

Jing-Huan Li  1 , Xiao-Ying Xie  1 , Lan Zhang  1 , Fan Le  1 , Ning-Ling Ge  1 , Li-Xin Li  1 , Yu-Hong Gan  1 , Yi Chen  1 , Ju-Bo Zhang  1 , Tong-Chun Xue  1 , Rong-Xin Chen  1 , Jing-Lin Xia  1 , Bo-Heng Zhang  1 , Sheng-Long Ye  1 , Yan-Hong Wang  1 , Zheng-Gang Ren  1
Affiliations

Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma

Jing-Huan Li et al. World J Gastroenterol. .

Abstract

Aim: To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC).

Methods: In this retrospective study, 132 patients with unresectable HCCs larger than 10 cm were treated with hepatic infusion of oxaliplatin and 5-fluorouracil followed by Lipiodol chemoembolization. The primary endpoint was overall survival (OS). Sixteen-week disease-control rate, time to progression (TTP), and major complications were also studied. Univariate and multivariate analyses were performed to identify prognostic factors affecting OS and TTP.

Results: A total of 319 procedures were performed in the 132 patients. Eleven (8.3%) patients received radical resection following TACE treatment (median time to initial TACE 4.3 ± 2.3 mo). The median OS and TTP were 10.3 and 3.0 mo respectively, with a 50.0% 16-wk disease-control rate. Major complications were encountered in 6.0% (8/132) of patients following TACE and included serious jaundice in 1.5% (2/132) patients, aleukia in 1.5% (2/132), and hepatic failure in 3.0% (4/132). One patient died within one month due to serious hepatic failure and severe sepsis after receiving the second TACE. The risk factor associated with TTP was baseline alpha-fetoprotein level, and vascular invasion was an independent factor related to OS.

Conclusion: Hepatic infusion of oxaliplatin and 5-fluorouracil followed by lipiodolized-chemoembolization is a safe and promising treatment for patients with HCCs larger than 10 cm in diameter.

Keywords: 5-fluorouracil; Hepatic infusion; Large hepatocellular carcinoma; Oxaliplatin; Transarterial chemoembolization.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival curves. A: The Kaplan-Meier overall survival curve for all 132 patients in this study; B: The factor that significantly influenced survival was revealed by multivariate analysis. P value stratified log-rank test; Hazard ratio was obtained with the Cox model; TACE: Transarterial chemoembolization.
Figure 2
Figure 2
Time to progression curve. The Kaplan-Meier time to progression curve for all 132 patients in this study. TACE: Transarterial chemoembolization.
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Takayasu K. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. Oncology. 2013;84 Suppl 1:28–33. - PubMed
    1. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225–235. - PubMed
    1. Cohen MJ, Bloom AI, Barak O, Klimov A, Nesher T, Shouval D, Levi I, Shibolet O. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol. 2013;19:2521–2528. - PMC - PubMed
    1. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;(3):CD004787. - PMC - PubMed

MeSH terms